Détail du document
Identifiant

oai:HAL:hal-03212590v1

Sujet
Parkinson's disease cognition kininogen-1 neurodegeneration [SDV]Life Sciences [q-bio]
Auteur
Markaki, Ioanna Bergström, Sofia Tsitsi, Panagiota Remnestål, Julia Månberg, Anna Hertz, Ellen Paslawski, Wojciech Sorjonen, Kimmo Uhlén, Mathias Mangone, Graziella Carvalho, Stephanie Rascol, Olivier Meissner, Wassilios, G Magnin, Eloi Wüllner, Ullrich Corvol, Jean-Christophe Nilsson, Peter Svenningsson, Per
Langue
en
Editeur

HAL CCSD;Wiley

Catégorie

CNRS - Centre national de la recherche scientifique

Année

2020

Date de référencement

15/12/2023

Mots clés
impairment kininogen-1 repeatable battery parkinson patients levels dementia neuropsychological status pd assessment
Métrique

Résumé

International audience; Background: Cognitive impairment is common in patients with PD.

Core markers of Alzheimer's dementia have been related also to PD dementia, but no disease-specific signature to predict PD dementia exists to date.Objectives: The aim of this study was to investigate CSF markers associated with cognition in early PD.Methods: A high-throughput suspension bead array examined 216 proteins in CSF of 74 PD patients in the AETIONOMY project.

Cognitive function was assessed with Repeatable Battery for the Assessment of the Neuropsychological Status, Montreal Cognitive Assessment, and Mini-Mental State Examination.Results: Of 69 patients with complete data, 34 had high (≥90) and 35 had low Repeatable Battery for the Assessment of the Neuropsychological Status total score (<90).

Of 14 proteins in CSF that differed in levels between groups, increased kininogen-1, validated with several antibodies, was independently associated with lower Repeatable Battery for the Assessment of the Neuropsychological Status and Montreal Cognitive Assessment scores after adjustment for confounders.Conclusions: Kininogen-1 levels in CSF may serve as a marker of cognitive impairment in PD.

© 2020 The Authors.

Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Markaki, Ioanna,Bergström, Sofia,Tsitsi, Panagiota,Remnestål, Julia,Månberg, Anna,Hertz, Ellen,Paslawski, Wojciech,Sorjonen, Kimmo,Uhlén, Mathias,Mangone, Graziella,Carvalho, Stephanie,Rascol, Olivier,Meissner, Wassilios, G,Magnin, Eloi,Wüllner, Ullrich,Corvol, Jean-Christophe,Nilsson, Peter,Svenningsson, Per, 2020, Cerebrospinal Fluid Levels of Kininogen‐1 Indicate Early Cognitive Impairment in Parkinson's Disease, HAL CCSD;Wiley

Document

Ouvrir

Partager

Source

Articles recommandés par ES/IODE IA

MELAS: Phenotype Classification into Classic-versus-Atypical Presentations
presentations mitochondrial strokelike patients variability phenotype clinical melas
Protocol for the promoting resilience in stress management (PRISM) intervention: a multi-site randomized controlled trial for adolescents and young adults with advanced cancer
cancer quality of life anxiety depression hope coping skills communication intervention randomized ayas outcomes resilience care trial cancer prism-ac advanced